496 related articles for article (PubMed ID: 22842366)
1. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
3. Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression.
Zhigang H; Qi Z; Jugao F; Xiaohong C; Wei Z; Hong W; Hu H; Na M; Zheng Y; Demin H
J Otolaryngol Head Neck Surg; 2009 Aug; 38(4):440-8. PubMed ID: 19755084
[TBL] [Abstract][Full Text] [Related]
4. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
[TBL] [Abstract][Full Text] [Related]
5. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
6. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
7. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
8. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
[TBL] [Abstract][Full Text] [Related]
9. [The relationship between multi-drug resistance gene expression and drug resistance of ovarian carcinoma].
Zhu L; Lang J; Shen K
Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):462-6. PubMed ID: 9639738
[TBL] [Abstract][Full Text] [Related]
10. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
11. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs.
Sun Y; Zhang T; Gao P; Meng B; Gao Y; Wang X; Zhang J; Wang H; Wu X; Zheng W; Zhou G
Breast Cancer Res Treat; 2010 Jun; 121(3):591-9. PubMed ID: 19693666
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
13. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
14. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella.
Deng J; Guo Y; Jiang Z; Yang M; Li H; Wang J
J Obstet Gynaecol Res; 2015 Apr; 41(4):615-22. PubMed ID: 25370788
[TBL] [Abstract][Full Text] [Related]
16. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
19. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
